Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.2.2-8. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.2.2-9. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.2.2-10. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation car- riers: a European cohort study. J Am Coll Cardiol. 2012;59: 493 500. S7.2.2-11. K ber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221 30. S7.2.2-12. Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention implantable cardioverter defibillators in patients with nonischemic cardiomyopathy: a meta-analysis. JAMA Cardiol. 2017;2:685 8. S7.2.2-13. Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter-defi- brillator for nonischemic cardiomyopathy: an updated meta-analy- sis. Circulation. 2017;135:201 3. 7.2.3. Treatment of Recurrent VA in Patients With NICM S7.2.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165 71. S7.2.3-2. Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla- tion of ventricular tachycardia in dilated nonischemic cardiomy- opathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728 36. S7.2.3-3. Tung R, Vaseghi M, Frankel DS, et al. 